摘要
目的探讨蒙药红花止血八味、西药、蒙药西药联合这3种治疗方案对儿童原发免疫性血小板减少症(ITP)的有效性和经济性。方法纳入2012年5月—2020年12月在内蒙古自治区国际蒙医院及内蒙古人民医院门诊、住院确诊为ITP的患儿224例行回顾性分析,根据用药情况分为蒙药组(66例)、西药组(81例)、蒙药西药联合组(77例)。蒙药组予以蒙药红花止血八味(古日古木-8)治疗,西药组予以静注人免疫球蛋白(IVIG)+醋酸泼尼松片(PAT)治疗,蒙药西药联合组予以红花止血八味+静注人免疫球蛋白+醋酸泼尼松片治疗。采用最小成本法对3种治疗方案进行药物经济学评价。结果3组患儿基本资料比较,蒙药组初始血小板计数高于西药组和蒙药组(P=0.007),其余指标比较差异均无统计学意义(P>0.05)。3组患者出血部位差异均无统计学意义(P>0.05)。蒙药组、西药组、蒙药西药联合组治疗儿童ITP的有效率分别为86.36%、82.71%、89.61%,比较差异无统计学意义(P>0.05)。蒙药组不良反应发生率明显低于蒙药西药联合组与西药组(P<0.05)。蒙药组治疗成本低于西药组与蒙药西药联合组(P<0.001),蒙药西药联合组的成本低于西药组(P<0.05)。结论治疗儿童ITP蒙药疗效好,不良反应发生率低,且蒙药组最为经济,蒙药西药联合组次之。
Objective To evaluate the effectiveness and economics of three therapeutic in the treatment of immune thrombocytopenia in children.Methods A retrospective analysis was conducted on 224 pediatric patients diagnosed with ITP at the International Mongolian Hospital and Inner Mongolia People's Hospital in Inner Mongolia Autonomous Region from May 2012 to December 2020.They were divided into Mongolian medicine group(66 cases),Western medicine group(81 cases),and Mongolian medicine Western medicine combination group(77 cases)based on their medication status.The Mongolian medicine group was treated with the Mongolian medicine safflower hemostatic eight flavors(Guri Gumu-8),the Western medicine group was treated with intravenous injection of human immunoglobulin(IVIG)+prednisone acetate tablets(PAT),and the Mongolian medicine Western medicine combination group was treated with safflower hemostatic eight flavors+intravenous injection of human immunoglobulin+prednisone acetate tablets.Use the minimum cost method to evaluate the pharmacoeconomics of three treatment plans.Results Comparison of basic information of 3 groups of children with ITP showed that the initial platelet count in the Mongolian medicine group was higher than that in the Western medicine group and the Mongolian-Western medicine group(P=0.007),while the other indicators showed no statistically significant differences(P>0.05).There was no statistically significant difference in bleeding sites among the 3 groups of patients(P>0.05).The effective rates of treatment with Mongolian medicine,Western medicine,and Mongolian-Western medicine combination were 86.36%,82.71%,and 89.61%,respectively,with no statistically significant differences(P>0.05).The incidence of adverse reactions in the Mongolian medicine group was significantly lower than that in the Mongolian-Western medicine group and the Western medicine group(P<0.05).The treatment cost of the Mongolian medicine group was lower than that of the Western medicine group and the Mongolian-Western medicine group(
作者
敖格日乐图
肖志彬
曹林娟
赛罕其其格
张晓娟
耿甄彦
宝山
AOGE Riletu;XIAO Zhibin;CHAO Linjuan;SAIHAN Qiqige;ZHANG Xiaojuan;GENG Zhenyan;BAO Shan(Department of Pharmacy,Inner Mongolia international hospital of Mongolian medicine,Hohhot 010065,China;School of Pharmacy,Inner Mongolia Medical University,Hohhot 010110,China;Department of Pharmacy,Inner Mongolia People's Hospital,Hohhot 010173,China)
出处
《西部医学》
2023年第6期894-898,共5页
Medical Journal of West China
基金
内蒙古自治区自然科学基金项目(2020MS08148)
自治区卫生计生科研计划项目(201703041)
内蒙古自治区蒙医药研究所项目(2016YS04)。
关键词
蒙药
西药
蒙药西药联合
原发免疫性血小板减少症
药物经济学
Mongolian medicine
Western medicine
Mongolian medicine combine with western medicine
Primary immune thrombocytopenia
Pharmacoeconomics
